Cytokinetics (CYTK) Stock
Muscle therapy developer partnering with major pharmaceutical firms. Here's the price, business snapshot, and what's worth knowing about Cytokinetics in October 2026.
Cytokinetics Inc (CYTK) is a clinical‑stage biopharmaceutical company developing therapies that modulate muscle contractility to treat heart and neuromuscular diseases. Its strategy is pipeline‑driven: value depends on clinical trial readouts, regulatory decisions and partner agreements rather than steady product revenue today. The company partners with larger pharmaceutical firms to share development costs and access commercial resources, which can de‑risk programmes but also affect future upside. With a market capitalisation of about $6.91 billion, investor expectations reflect potential clinical and commercial success. Key catalysts include clinical data releases and regulatory milestones; conversely, negative trial outcomes or delays can materially affect the share price. Biotech stocks tend to be volatile and may require a long‑term horizon. This summary is for general educational purposes only and is not personalised financial advice—speak to an independent adviser to assess suitability for your circumstances.
Cytokinetics (CYTK) Stock Forecast
Analyst price target, next 12 months
$96.16
+57.0% vs today's $61.23
Price range over the last 12 months
Close to its 12-month low
Analysts covering Cytokinetics have a consensus 12-month target of $96.16, above the current price of $61.23.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cytokinetics' stock with a target price of $96.16, indicating strong potential for growth.
Financial Health
Cytokinetics is generating solid revenue and cash flow, with a healthy gross margin supporting profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially move the share price, though outcomes are binary and performance can vary.
Partner Collaborations
Deals with larger pharmas can provide funding and commercial reach, but may mean shared revenue and less autonomy.
Science Focus
Targeting muscle contractility is a differentiated scientific approach with broad potential, yet scientific and regulatory hurdles remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
